Amgen (AMGN) Depreciation & Amortization (CF) (2009 - 2026)

Amgen has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $1.1 billion in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 17.08% year-over-year to $1.1 billion in Q2 2026; TTM through Jun 2026 was $4.7 billion, a 15.47% decrease from a year earlier, with the FY2025 full-year figure at $5.2 billion, down 7.6% from the prior year.
• Depreciation & Amortization (CF) was $1.1 billion for Q2 2026 at Amgen, roughly flat from $1.1 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.4 billion in Q2 2024, with the low at $828.0 million in Q2 2022.
• Average Depreciation & Amortization (CF) over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2025.
• The sharpest annual moves came in 2024 and 2026: Depreciation & Amortization (CF) surged 56.25% in 2024, then declined 19.54% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $911.0 million in 2022, then surged by 51.48% to $1.4 billion in 2023, then gained by 1.23% to $1.4 billion in 2024, then fell by 18.97% to $1.1 billion in 2025, then fell by 1.77% to $1.1 billion in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.1 billion (Q2 2026), $1.1 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.